Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
11 studies found for:    weill | Open Studies | "Intestinal Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders
Conditions: Ampullary Cancer;   Duodenal Cancer;   Bile Duct Cancer;   Bile Duct Disorders;   Gallstones;   Obstructive Jaundice;   Pancreatic Disorders (Noncancerous);   Colorectal Cancer;   Esophageal Cancer;   Barrett's Esophagus;   Gastric Malignancies;   Pancreatic Cancer;   Pediatric Gastroenterology;   Cholangiocarcinoma;   Pancreatic Pseudocysts;   Acute and Chronic Pancreatitis;   Recurrent Pancreatitis;   Cholangitis;   Bile Leak;   Biliary Strictures;   Pancreatic Divisum;   Biliary and Pancreatic Stones;   Choledocholithiasis
Intervention: Procedure: Interventional Endoscopy
2 Recruiting Endoscopic Resection Multicenter Registry
Conditions: Gastrointestinal Neoplasms;   Gastrointestinal Disease;   Gastric Cancer;   Gastric Neoplasm;   Gastric Polyp;   Esophageal Neoplasms;   Duodenal Neoplasms;   Duodenal Polyp;   Stomach Neoplasm;   Stomach Polyp;   Neoplasms;   Colon Polyp;   Colon Neoplasm
Intervention: Procedure: Endoscopic Resection
3 Recruiting High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
Conditions: Colorectal Cancer;   Pancreatic Cancer;   Lung Cancer
Intervention: Drug: Vitamin C
4 Recruiting 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Conditions: Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
Intervention: Drug: 177Lu-J591
5 Recruiting Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer
Conditions: Pancreatic Cancer;   Colorectal Cancer
Intervention: Biological: Cancer macrobead placement in abdominal cavity
6 Recruiting Nonrandomized, Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant Colorectal Cancer
Condition: Colorectal Cancers
Intervention: Biological: RENCA macrobeads
7 Not yet recruiting Preoperative Radiotherapy and E7046 in Rectum Cancer
Condition: Neoadjuvant Therapy in Rectal Cancer
Interventions: Drug: E7046;   Radiation: Long Course Chemoradiotherapy (LCRT);   Radiation: Short Course Radiotherapy (SCRT);   Drug: capecitabine;   Drug: folinic acid/5-FU/oxaliplatin (mFOLFOX-6)
8 Recruiting Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
Condition: Lynch Syndrome
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Naproxen;   Other: Placebo
9 Recruiting A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection
Conditions: Rectal Cancer;   Rectosigmoid Cancer
Interventions: Device: PINPOINT;   Device: SPY Elite
10 Recruiting PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Condition: Colorectal Cancer
Interventions: Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
11 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Carcinoma Breast Stage IV;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Urinary Bladder Neoplasms;   Cervical Cancer;   Endometrial Cancer;   Follicular Thyroid Cancer;   Glioblastoma Multiforme
Intervention: Drug: IMMU-132

Study has passed its completion date and status has not been verified in more than two years.